Genmab — November 2012
-
off label det er jo kun et begreb for de læger der udskriver. Den har jo per definition ingen label i et klinisk forsøg
-
Ingen af jer der kan bruge et sommerhus i minnesota for 300 mio. kr. ?
-
godt køkken- store gryder
-
In CLL primary cases (n=8) tested, DARA (14-43% lysis) was generally superior or at least equally effective (mean+/-SD=28,78 +/- 9,78) in inducing ADCC as compared to the anti-CD20 antibodies ofatumumab (mean+/-SD=21,35 +/- 15,71) and rituximab (mean+/-SD=29,30 +/- 15,90)
-
-
-
Eller hvad med 82 % CR i relapsed Hodgkins Lymphoma (!) https://ash.confex.com/ash/2012/webprogram/Paper46803.html
-
pretty good stuff!
-
strategiskifte i dansk biotek henimod orphan drugs http://medwatch.dk/secure/Medicinal___Biotek/article4917876.ece?1353583140740
-
netop det marked SPPI satser på aka
-
Fusilev, FOlotyn, belinostat, Apaziquone. Alle Orphan drugs
-
købte lidt flere i det her niveau. Den har fundet lidt styrke igen
-
nej nej rolig nu min ven
-
De koster godt nok det samme pr. aktie målt i kr.
-
22.500 SPPI og 7500 genmab pt.
-
Vil gerne have genmab over 90 og også 100 før jeg supplerer. men går på ingen måde over 10.000 stk. før jeg har set CLL frontline data og Janssen udviklingsprogram for dara
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind